Summary The neural cell adhesion molecule (NCAM) is highly expressed on the surface of small-cell-lung cancer (SCLC) cells. We have produced a monoclonal antibody, NY3D11, that binds to NCAM to investigate whether this antigen could be used to develop antibody-directed therapy for SCLC. 1251-labelled IgG and F(ab')2 fragments of NY3D11 localized selectively in human SCLC xenografts grown in nude mice. The human biodistribution of 131 I-labelled NY3D11 after intravenous administration was investigated by gamma-camera imaging in six patients with SCLC. Three patients received IgG and three received F(ab')2. No evidence of localization to primary tumours or metastases was seen and antibody accumulated rapidly in the liver and bone marrow. The probable explanation for this distribution is that NY3D11 reacted with soluble NCAM or natural killer cells that possess the CD56 (NCAM) antigen.
The mortality of patients with small-cell lung cancer (SCLC) remains greater than 90% at 2 years after diagnosis and new therapeutic approaches are urgently needed to improve the outcome of the disease (Souhami et al, 1990 ). The tumour is characterized by its initial responsiveness to chemotherapy, producing complete remission in about 50% of patients and early relapse. Eradication of persistent micrometastases at the end of chemotherapy would prevent the development of chemoresistant tumour relapse. Antibody-directed therapy is one strategy used to target therapy specifically to the tumour site. Monoclonal antibodies recognizing tumour-associated surface antigens have been shown to localize specifically in many different tumour types. Therapy is most likely to be effective in small tumour foci when the total tumour burden is low as antibody uptake is most efficient (Pedley et al, 1987; Olabiran et al, 1994) . Adjuvant antibody therapy in patients with colorectal cancer has produced encouraging results (Reithmuller et al, 1994) and antibody-directed therapy of micrometastases of SCLC in the adjuvant setting could also be an effective new treatment.
The neural cell adhesion molecule (NCAM) is strongly expressed on the surface of SCLC cells (Souhami et al, 1991; Rygaard et al, 1992) . Anti-NCAM monoclonal antibodies localize to SCLC xenografts in nude mice and produce regression of tumours when conjugated to a therapeutic dose of radioisotope (Boerman et al, 1991; Hosono et al, 1994) . NCAM is also expressed by normal tissues including neural tissue, muscle, thyroid epithelium, testicular Leydig cells and natural killer (NK) cells in blood. It exists in membrane-associated forms and a soluble form that can be detected in the serum of patients with SCLC (Jaques et al, 1993) . Serum NCAM levels are raised in patients with active disease and in relapse, suggesting that this antigen could be a useful target for therapy of micrometastases .
We have produced a murine monoclonal antibody, NY3D11, against the NCAM molecule on SCLC. The purpose of this study was to investigate the biodistribution of radiolabelled NY3D11 whole immunoglobulin and its F(ab')2 fragments in nude mice bearing SCLC xenografts and to perform a localization study in patients with SCLC.
MATERIALS AND METHODS Antibodies
The monoclonal antibody NY3D 1 1 was raised after immunization of RBS/DNJ mice (Robertsonian 8:12 translocation) with SCLC cell line UCH10. Spleen cells were fused with the Fox NY, NS1 variant myeloma line. For details see Olabiran et al (1994) . In common with most other anti-NCAM monoclonal antibodies, NY3D1 1 binds to immunodominant epitopes located in the 'stem region' C-terminal of the fifth Ig-like domain of the NCAM molecule (Gerardy-Schahn et al, 1994) . The antibody for patient administration was purified by affinity chromatography on protein A-Sepharose from tissue culture supernatant (kindly produced by Celltech) and tested before clinical use according to guidelines in the Operation Manual for the Control of Production, Preclinical Toxicity and Phase I Trials of Anti-tumour Antibodies and Drug-Antibody Conjugates (1986). F(ab')2 fragments F(ab')2 fragments of NY3D 1 were prepared from whole antibody by bromelain digestion (Mariani et al, 1991) . In brief, freshly activated and desalted bromelain was added to the antibody in 0.1 M sodium acetate/3 mM EDTA pH 5.5 at a ratio of 1:50 (bromelain-antibody). The mixture was incubated for 1 h at 37°C, cooled to 4°C and a small amount of 0.1 M sodium hydroxide added to bring the pH to 6.0. The antibody/bromelain reaction mixture was immediately applied to a SP Sepharose column that was washed with a 5-CV (column volume) gradient of 0.2 M sodium chloride/0. 1 M sodium acetate pH 6.0 to separate the F(ab')2 fragments. F(ab')2 was then passed down a protein A column to remove residual whole IgG. The purity of the F(ab')2 product was assessed using sodium dodecyl sulphate polyacrylamide gel and highperformance liquid chromatography before patient administration. 
Animal studies Establishment of xenografts in nude mice
The human small-cell lung cancer cell line UCH1O or H69 was used to establish a xenograft model subcutaneously in the flanks of nude (nu/nu) mice. The mice were female, 2-3 months old and weighed between 20 and 25 g. Subsequent passaging of tumours was carried out by subcutaneous implantation of small tumour pieces (approximately 1 mm3). The biodistribution study was commenced when the tumours reached a size of approximately 1.0 cm3. Immediately before the study, a xenograft tumour was examined for antigen expression by immunohistochemistry and binding of NY3D 11 antibody and its F(ab')2 fragments was confirmed.
Immunohistochemistry
Immunohistochemical reactivity of NY3D 11 with bone marrow and xenograft tissue was assessed using an avidin-biotin peroxidase technique. Xenograft tissue was snap frozen in isopentane, cooled in liquid nitrogen and 6 jm cryostat sections were cut. Bone marrow smears and cryostat sections were fixed before immunohistochemistry with acetone for 10 min.
Biodistribution study At an adjacent site 0.1 ml of 0.9% saline was injected intradermally and the skin reaction at both injection sites was compared after 15 min. If erythema at the test site was greater than at the control site, intravenous administration of antibody did not proceed. The antibody (0.5-1 mg) was injected intravenously over 5 min.
Study parameters Gamma camera imaging
Patients were scanned at 24, 48 and 72 h after injection of antibody. Scanning was performed using a large field of view gamma-camera with a high-energy parallel-hole collimator and an on-line computer. 
Patient studies
The patient characteristics are summarized in Table 1 . There were no positive skin reactions and no immediate or delayed adverse effects after injection of the antibody. No haematological or biochemical toxicity was observed. The first three subjects were studied with NY3D1 1 IgG after mouse studies indicated that uptake of IgG in tumour xenografts was higher than for F(ab')2. No antibody localization was detected in primary tumours or metastases but accumulation in the bone marrow (spine and pelvis) and liver was observed in all subjects. The spleen was visualized in one patient (subject 3). The mouse studies had shown that F(ab')2 might be more favourable for imaging (high tumour:blood ratio) and three further subjects were studied with NY3D1 1 F(ab')2. The results were similar to those of IgG. No primary tumours or metastases were imaged but antibody again accumulated in bone marrow and liver. First-phase clearance of radiolabelled antibody from blood was rapid with less than 25% of initial activity remaining at 24 h (Figure 4 ). Whole antibody and F(ab')2 were cleared at similar rates except in one patient (subject 4).
In vitro antibody studies Aggregation
Antibody showed no evidence of aggregation in vitro either before or after radiolabelling. Incubation of radiolabelled antibody with a patient serum or previously stored serum with high soluble NCAM did not produce aggregation. radiolabelled NY3D 11 demonstrated approximately 50% loss of immunoreactivity. When the iodogen method was used for subjects 3-6, there was only a small reduction of immunoreactivity after radiolabelling.
Immunohistochemistry of SCLC xenografts and normal bone marrow Immunohistochemistry of SCLC xenografts removed immediately before biodistribution studies confirmed that NY3D 11 whole IgG and its F(ab')2 fragments reacted with the tumour. After studies in humans demonstrated localization in bone marrow, immunohistochemistry on ten normal bone marrow samples was performed to investigate whether this distribution could be explained by reaction with a cellular element in bone marrow. These studies showed no evidence of antibody binding to normal bone marrow cells.
FACS analysis
The H69 SCLC cell line bound at least six to seven times as much NKH1 as NY3D 11, despite the use of NY3D 11 over a concentration range of 1-100 ,ug ml'. Similarly, the percentage of CD8, CD16 or CD57 positive cells (NK cells) that stained with NY3D 1I or NKH1 was always much less for NY3D 11 than NKH1 (approximately 40% and 90% respectively) and the mean fluorescence intensity (MFI) of NKH1 on NK cells was six-to sevenfold greater than that of NY3Dl 1. However, the MFI values suggested that NK cells could still bind large amounts of NY3Dl 1.
DISCUSSION
These studies demonstrate that NY3D 11 localized well to SCLC xenografts in mice but not to SCLC tumours in patients in whom it was cleared rapidly from blood and accumulated in bone marrow and liver. A previous study in patients with SCLC using the NCAM monoclonal MAb 123C also found no localization to primary tumours, although a single liver metastasis was detected (Michalides et al, 1994) . This negative result occurred despite immunoscintigraphy studies in mice that suggest that MAb 123C3 has superior localization compared with other cluster-1 antibodies because of its internalization (Kwa et al, 1996) . However, it is clear that other anti-NCAM antibodies that do not internalize can also localize well in mouse studies (Boerman et al, 1991; Waibel et al, 1993; Hosono et al, 1994 ) and the present study further highlights that successful localization of antibodies in mice is not necessarily reproduced in human studies. The reasons for this disparity between mice and man need to be understood for the successful future development of anti-NCAM antibodies. The reticuloendothelial system (RES) can recognize and remove foreign particles from the circulation. Some antibody binding and uptake may occur through non-specific Fc receptor interactions. Blood clearance is also a function of size of the antibody. Murine F(ab')2 fragments are cleared more rapidly from blood than intact IgG in mice but clearance in man is similar (Lane et al, 1994) . We observed a similar blood distribution of intact antibody and F(ab')2 fragments in patients implying that Fc interactions were not an important factor affecting blood clearance. Aggregation of antibody could also explain the observed distribution but there was no evidence from gel chromatography that aggregation had occurred during storage or after radiolabelling. The possibility that antibody combined with soluble NCAM in serum to form aggregates was also considered but no aggregation was seen after incubation with patient serum or serum containing high levels of soluble NCAM. Although Sepharose chromatography did not suggest binding to soluble NCAM, low-affinity antibody may occasionally not survive column chromatography. NY3D11 appears to have a relatively low affinity for NCAM and therefore aggregation cannot be completely excluded.
Gamma-camera scanning demonstrated accumulation in spine, pelvis and ribs that suggested that antibody was localizing in the bone marrow. However, no binding of antibody was seen in any of the normal bone marrow aspirates examined by immunohistochemistry. It is known that natural killer (NK) cells express NCAM (CD56) (Hida et al, 1991 The importance of immunoreactivity of an antibody with its epitope for tumour localization remains uncertain. Some authors suggest that antibody uptake and penetration into tumours is enhanced by high affinity radioimmunoconjugates (Schlom et al, 1992) , whereas others propose that interaction of high-affinity antibodies at the surface of a tumour prevents penetration (Fujimori et al, 1989) . Radioactive labelling of NY3D1 1 by the chloramine-T method led to a 50% loss of immunoreactivity compared with unlabelled antibody. After the labelling technique was changed to the iodogen method, the reduction in immunoreactivity was small. However, improvement in immunoreactivity failed to enhance tumour localization of antibody.
The accessibility of epitopes on tumour cells is also likely to be important for successful antibody localization (Pervez et al, 1988) . The limited success of radioimmunotherapy and wide variations in antibody localization amongst patients with cancers of the same histology has been attributed in part to heterogeneity of antigen distribution (Edwards, 1985) . The distribution of NCAM expression in SCLC tumours in vivo has not been studied as it is difficult to obtain tumour samples, but accessibility of NCAM epitope to circulating antibodies in patients may be restricted. Antigens in vivo may be expressed at preferential sites (Pervez et al, 1989 ) and the basal lamina may represent a physical barrier to extravasated antibodies (Dvorak et al, 1991) . In colorectal adenocarcinomas, CEA epitopes expressed on the lumenal surface of malignant acini or in the cytoplasm may be inaccessible to antibodies in vivo, whereas epitopes on the basal or basolateral aspects of glandular structures are more readily accessible . However, it has been shown that CEA epitopes on lung cancer are accessible to circulating antibodies. When CEA was targeted in 21 patients with active SCLC, tumour was successfully imaged in 13 patients (62%) and 18 out of 38 known disease sites were imaged (Macmillan et al, 1993) . This antigen is a promising target for further studies. The epithelial glycoprotein EGP-2 on SCLC has also been successfully targeted in patients (Kosterink et al, 1995) . Six patients with SCLC were studied with indium-labelled monoclonal antibody MOC-3 1, which was identified as a cluster 2 antibody at the First International Workshop on SCLC antigens. Scintigraphy detected primary tumour or metastases in five patients and further studies are indicated.
In summary, reaction with soluble NCAM or circulating NK cells was the most likely reason for the failure of NY3Dll to localize to tumour in these studies. NCAM does not now appear to be a suitable target for antibody directed therapy in SCLC but the lung cancer antigen workshops have identified other surface antigens which should be investigated.
